<DOC>
	<DOCNO>NCT01499823</DOCNO>
	<brief_summary>The aim present study ass whether new method quantify therapy-associated hemodynamic alteration base DCE MR imaging may help distinguish pseudoprogression true progression patient high grade glioma , receive CCRT .</brief_summary>
	<brief_title>Permeability Map Distinguish Progression From Pseudoprogression High-Grade Glioma</brief_title>
	<detailed_description>Combination temozolomide radiation significantly prolong survival compare radiation alone become standard treatment glioblastoma multiforme ( GBM ) . Response assessment GBM difficult result frequent occurrence early imaging change indistinguishable tumor progression , term pseudoprogression . The majority patient remain clinically stable . It often unclear whether current therapy maintain second-line therapy initiate . The incidence pseudoprogression concurrent chemoradiation is15 % 30 % . A potential mechanism pseudoprogression radiation-induced vascular change may lead focal transient increase gadolinium enhancement . Dynamic contrast-enhanced ( DCE ) MR image provide noninvasive mean quantify tumor vascular property .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>Among patient highgrade glioma ( glioblastoma multiforme anaplastic astrocytoma ) , receive concurrent chemoradiation ( CCRT ) temozolomide , patient show measurable enhance portion ( 1 cm long diameter accord RANO criterion ) immediate f/up MRI CCRT . Among patient highgrade glioma ( glioblastoma multiforme anaplastic astrocytoma ) , receive concurrent chemoradiation ( CCRT ) temozolomide , patient show measurable enhance portion ( 1 cm long diameter accord RANO criterion ) immediate f/up MRI CCRT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Permeability Map</keyword>
	<keyword>High-Grade Glioma</keyword>
</DOC>